Adaptimmune Therapeutics Plc Net Income

Adaptimmune Therapeutics Plc (ADAP) currently reports a net income of $-170M as of June 2025. That compares with $-73M in the prior-year period — down 133.1% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Adaptimmune Therapeutics Plc's net income history and peer comparisons.

Adaptimmune Therapeutics Plc's net income decreased from $-73M to $-170M — a 133.1% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptimmune Therapeutics Plc's net income of $-170M is lower than the Healthcare sector average of $16B. That is roughly 101.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Adaptimmune Therapeutics Plc reported $-170M in net income as of June 2025. That compares with $-73M in the prior-year period — down 133.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-170M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics Plc, and consider following ADAP for alerts when major investors trade the stock.